Gastritis-Pipeline Review, H2 2016
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019
Description Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors. Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/148545 . Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastritis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Gastritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 4 and 2 respectively.Gastritis. Gastritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/148545 . For more information contact sales@orbisresearch.com Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Gastritis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Gastritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019
registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Gastritis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Gastritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Gastritis (Gastrointestinal) Browse Complete Report @ http://www.orbisresearch.com/reports/index/gastritis-pipeline-reviewh2-2016 . List of Figures Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Mechanism of Actions, H1 2016 17 Number of Products by Stage and Mechanism of Actions, H1 2016 17 Number of Products by Stage and Routes of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 20
For any enquires before buying, connect with us @ enquiry@orbisresearch.com About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. Contact Information: Hector Costello Senior Manager – Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A. Phone No.: +1 (214) 884-6817; +9164101019 Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research Follow us on Twitter: https://twitter.com/orbisresearch
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019